In the past two years, BNDES has received a growing number of consultations, both formal and prospective, from foreign companies
in the health industry that are interested in the Brazilian market. Yes, we do expect more—and that these activities come
to be real investments in the Brazilian health industry. Investments that contribute to the established industrial technology
and that contribute to the challenge of increasing the access of the Brazilian public to health products and services will
be very welcome.
Brazil's regulatory system and healthcare policies seem to be stable and well-respected on a global scale, which have contributed
to its role as a pharmerging nation. What components of this governance structure hold advantages for outside bio/pharmaceutical
companies wanting to do business in Brazil (e.g., IP rights, taxes, regulatory approvals, market access)?
Companies that wish to invest in the Brazilian health industry will encounter an extremely favorable environment, especially
for projects regarding the abovementioned question. Brazil has a regulatory regime and intellectual property environment that
are in compliance with global standards, as well as a scientific and technological base that is consolidated and expanding.
Finally, regarding long-term credit, BNDES and other government agencies offer favorable conditions to support industrial
investments in production facilities as well in research, development, and innovation activities.
Brazil is known as a "pharmerging" market by the bio/pharmaceutical industries in North America and Europe. How do you view
this label? How do you see your country in the global marketplace in terms of the bio/pharmaceutical space?
Today, Brazil is among the 10 largest economies in the world. With a population of 180 million, a vast territory, and immense
mineral wealth, the country is positioned as a promising economy. With a robust middle class, a diversified industrial base,
a sustainable energy matrix, and a stable democracy that is anchored in solid institutions, the country is clearly on a path
for growth—led not only by internal consumption, but also by a significant volume of exports. In this scenario, Brazil can
legitimately aspire to be one of the world's five foremost economies.
As far as the health industry is concerned, the scenario is even more promising as it is challenging. As mentioned, the income-transfer
programs, together with economic growth, have brought 36 million Brazilian out of poverty to become real citizens able to
consume goods and services. The improvements in quality of life of Brazilians have made demographic changes that will give
Brazil, in just a few decades, a demographic pyramid similar to that of Europe. Life expectancy in Brazil is currently 73
years old. The change in the epidemiological profile of the populace is also impressive: today, the average Brazilian has
more chronic-degenerative diseases than infecto-contagious illnesses. At the same time, it is important to point out the ambitious
public health system which covers more than 100 million people. According to the Constitution of Brazil, health is the right
of everyone and it is an obligation of the State to provide it.
Our pharmaceutical industry, which today holds the 7th rank in the world, grows by double digits, without indications of slowing
down. Projections indicate that Brazil will occupy the 6th position by 2015. The Brazilian government has been stimulating
the industry by supporting and financing projects that contribute to reducing the vulnerabilities of our health system—a fact
that together with a continually improving regulatory regime have shown signs of the strategic nature of our health industry.
Therefore, in this promising scenario it is indeed possible to affirm that, more than having a label of 'pharmerging market,'
Brazil is has all the conditions to become a solid and developed pharmaceutical market in the short run, and it has huge opportunities
for those that wish to take part.
The growing occurrence of South–South trade is leading to some multinational companies (as well as nations) to question their
current market-growth strategies. How does your organization view South–South trade in terms of benefits, and perhaps disadvantages?
From our viewpoint, the increased volume of South–South trade reflects the search for opportunities and exchange among commercial
partners with complementary interests. Regarding Brazilian interest in developing a strong biotechnology industry in line
with national interests, our country is obviously seeking partnerships with enterprises and governments where this technological
wave has been consolidated, regardless of the regions or geographic location.